Drug Trial Radar · NCT01782326
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)
Last checked: Nov 19, 2026Latest source record: May 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,362
Actual
Start
Jul 2013
Primary completion
Sep 2015
Study completion Sep 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
QVA149Drug
QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)Drug
Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of COPD ExacerbationsTime frame: 52 weeks
Locations
499 sites in 43 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Ciudad de Buenos Aires, Argentina, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Caba, Buenos Aires, Argentina
Novartis Investigative Site
Lanus, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Buenos Aires F.D., Argentina
Novartis Investigative Site
Concepción del Uruguay, Entre Ríos Province, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
Novartis Investigative Site
Mendoza, Mendoza Province, Argentina
Novartis Investigative Site
Salta, Salta Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Novartis Investigative Site
Santa Fe, Santa Fe Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, Argentina
Novartis Investigative Site
San Miguel de Tucumán, Tucumán Province, Argentina
Novartis Investigative Site
Salzburg, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Feldbach, Austria, Austria
Novartis Investigative Site
Feldkirch, Austria, Austria
Novartis Investigative Site
Graz, Austria, Austria
Novartis Investigative Site
Grieskirchen, Austria, Austria
Novartis Investigative Site
Linz, Austria, Austria
Novartis Investigative Site
Thalheim bei Wels, Austria, Austria
Novartis Investigative Site
Wels, Austria, Austria
Novartis Investigative Site
Innsbruck, Tyrol, Austria
Novartis Investigative Site
Aalst, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Brussels, Belgium
Showing 40 of 499 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.